I-Mab

Yahoo Finance • 2 months ago

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range from 5 mg/kg Q2W up to 18 mg/kg Q3... Full story

Yahoo Finance • 2 months ago

I-Mab tumbles after announcing new business model

[Business Model concept on the gearwheels] AlexLMX I-Mab (NASDAQ:IMAB [https://seekingalpha.com/symbol/IMAB]) shares fell ~14% on Friday after the cancer drug developer announced a new “hub-and-spoke” business model, under which it plans... Full story

Yahoo Finance • 2 months ago

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwideIntention to pursue a H... Full story

Yahoo Finance • 3 months ago

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based... Full story

Yahoo Finance • 4 months ago

Which stocks are gapping on Wednesday?

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT MWYN [https://www.chartmill.com/stock/... Full story

Yahoo Finance • 4 months ago

I-Mab to accelerate investment in givastomig

[Cancer cells vis] koto_feja/E+ via Getty Images I-Mab (NASDAQ:IMAB [https://seekingalpha.com/symbol/IMAB]) said on Monday that it is accelerating investment in its lead drug candidate, givastomig, a bispecific antibody for cancer treatme... Full story

Yahoo Finance • 4 months ago

Form 6K I Mab For: 25 August

... Full story

Yahoo Finance • 4 months ago

I-Mab to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced tha... Full story

Yahoo Finance • 4 months ago

I-Mab Biopharma GAAP EPS of -$0.07 misses by $0.02

* I-Mab Biopharma press release [https://seekingalpha.com/pr/20206192-i-mab-reports-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:IMAB [https://seekingalpha.com/symbol/IMAB]): Q2 GAAP EPS of -$0.07 misses by... Full story

Yahoo Finance • 5 months ago

I-Mab completes enrollment for givastomig trial ahead of schedule

ROCKVILLE, Md. - I-Mab (NASDAQ:IMAB), a clinical-stage biopharmaceutical company with a market capitalization of $392 million, announced Monday that enrollment in the Phase 1b dose expansion cohorts for its bispecific antibody givastomig h... Full story

Yahoo Finance • 5 months ago

Unusual volume stocks are being observed in Wednesday's session.

Discover the stocks with unexpected trading volume in today's session on the US markets. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT TNON [https://www.chartmill.com/stock/quote/TNON/profile] 7.14% The... Full story

Yahoo Finance • 5 months ago

The trading volume of these stocks is deviating from the norm in today's session.

Which stocks have an unusual volume on Tuesday? [unusualvolume] TODAY'S UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT SVIIR [https://www.chartmill.com/stock/quote/SVIIR/profile] 1.82% 295.38K shares of SPRING VALLEY ACQUISI... Full story

Yahoo Finance • 5 months ago

Unusual volume stocks in Monday's session

Unusual volume stocks are being observed in Monday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock/quote/PBM/profile] 76.28% PSYENCE BIOMEDICAL LTD (NASDAQ:P... Full story

Yahoo Finance • 5 months ago

I-Mab to buy Bridge Health Biotech

[Magnifying glass and documents with analytics data lying on tabl] tonefotografia/iStock via Getty Images I-Mab (NASDAQ:IMAB [https://seekingalpha.com/symbol/IMAB]) said on Thursday that it has signed an agreement to acquire Bridge Health... Full story

Yahoo Finance • 5 months ago

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future milestones for givastomig due to Bridge H... Full story

Yahoo Finance • 6 months ago

I-Mab to Present at the BTIG Virtual Biotechnology Conference

ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced tha... Full story

Yahoo Finance • 6 months ago

I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025

I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts. On July 2, I-Mab announced the presentation of positive Phase 1b combination data for givastomig at the European Society for Medical Oncology Gastrointe... Full story

Yahoo Finance • 6 months ago

I-Mab reports 83% response rate for givastomig in gastric cancer study

ROCKVILLE - I-Mab (NASDAQ:IMAB), a clinical-stage biotech company currently valued at $188 million, announced positive Phase 1b data for its bispecific antibody givastomig in combination with nivolumab and mFOLFOX6 for gastric cancer treat... Full story

Yahoo Finance • 6 months ago

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host i... Full story

Yahoo Finance • 6 months ago

I-Mab's givastomig shows promising results in gastric cancer study

ROCKVILLE, MD - I-Mab (NASDAQ:IMAB), a clinical-stage biotech company whose stock has surged over 200% in the past six months, announced Monday that data from its first-in-human study of givastomig, a bispecific antibody targeting Claudin... Full story